PembrolizumabGiant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy following an off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1823卷 / 1期

关键词：

D O I：

10.1007/s40278-020-83915-6

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：287 / 287

相关论文

共 50 条

[21] AzacitidineDiarrhoea following off-label use: case report
Reactions Weekly, 2019, 1736 (1) : 48 - 48
[22] PrednisoloneInefficacy following off-label use: case report
Reactions Weekly, 2022, 1910 (1) : 405 - 405
[23] NivolumabPsoriasis following an off-label use: case report
Reactions Weekly, 2018, 1717 (1) : 214 - 214
[24] TocilizumabNeutropenia following off-label use: case report
Reactions Weekly, 2021, 1853 (1) : 446 - 446
[25] DaratumumabHypogammaglobulinemia following off-label use: case report
Reactions Weekly, 2019, 1744 (1) : 111 - 111
[26] GlibenclamideHypoglycaemia following off-label use: case report
Reactions Weekly, 2021, 1857 (1) : 162 - 162
[27] SunitinibCardiomyopathy following off-label use: case report
Reactions Weekly, 2023, 1971 (1) : 240 - 240
[28] CatequentinibPneumothorax following off-label use: case report
Reactions Weekly, 2022, 1925 (1) : 158 - 158
[29] FelbamateNeutropenia following off-label use: case report
Reactions Weekly, 2020, 1803 (1) : 111 - 111
[30] RituximabAgranulocytosis following off-label use: case report
Reactions Weekly, 2018, 1712 (1) : 482 - 482

← 1 2 3 4 5 →